TREAT Asia calls for expanded access to pediatric dolutegravir

It is urgent to facilitate access to HIV medicine dolutegravir (DTG), that can be used in Asia-Pacific infants and children with HIV.

In light of recent U.S. and European regulatory approvals of a dispersible version of pediatric DTG, amfAR’s TREAT Asia program recommends steps that national HIV programs and advocacy groups can take in order to secure access to this medicine as quickly as possible.

The complete brief is available here.